13G Filing: Sabby Capital and Moleculin Biotech Inc (MBRX)

Page 9 of 10 – SEC Filing

*This Reporting Person disclaims beneficial ownership over the securities
reported herein except to the extent of its pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement
is signed on behalf of a person by his authorized representative other
than an executive officer or general partner of the filing person,
evidence of the representative’s authority to sign on behalf of such
person shall be filed with the statement, provided, however, that a power
of attorney for this purpose which is already on file with the
Commission may be incorporated by reference. The name and any title of
each person who signs the statement shall be typed or printed beneath
his signature.

Note. Schedules filed in paper format shall include a signed original
and five copies of the schedule, including all exhibits. See
S.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute
Federal criminal violations (see 18 U.S.C. 1001).

EXHIBIT 1
———-

JOINT FILING AGREEMENT

The undersigned hereby agree that this Statement on Schedule 13G
with respect to the beneficial ownership of common shares of
Moleculin Biotech, Inc is filed jointly, on behalf of each of them.

Dated: January 8, 2018

Sabby Healthcare Master Fund, Ltd.

By: /s/ Harry Thompson
Name: Harry Thompson
Title: Authorized Person of TDF Management
Ltd., a Director

Sabby Volatility Warrant Master Fund, Ltd.

By: /s/ Harry Thompson
Name: Harry Thompson
Title: Authorized Person of TDF Management
Ltd., a Director

Sabby Management, LLC

By: /s/ Robert Grundstein
Name: Robert Grundstein
Title: Chief Operating Officer